Italia markets closed
FTSE MIB
33.812,44 +41,37 (+0,12%) Dow Jones
40.589,34 +654,27 (+1,64%) Nasdaq
17.357,88 +176,16 (+1,03%) Nikkei 225
37.667,41 -202,10 (-0,53%) Petrolio
76,44 -1,84 (-2,35%) Bitcoin EUR
62.713,51 +1.104,27 (+1,79%)
Takeda Pharmaceutical Company Limited (4502.T)
Tokyo - Tokyo Prezzo differito. Valuta in JPY.
Aggiungi a watchlist
Alla chiusura: 03:15PM JST
| Chiusura precedente | 4.239,00 |
| Aperto | 4.240,00 |
| Denaro | 4.242,00 x 0 |
| Domanda | 4.247,00 x 0 |
| Min-Max giorno | 4.228,00 - 4.263,00 |
| Intervallo di 52 settimane | 3.900,00 - 4.873,00 |
| Volume | |
| Media Volume | 3.692.352 |
| Capitalizzazione | 6,728T |
| Beta (mensile su 5 anni) | 0,50 |
| Rapporto PE (ttm) | 46,51 |
| EPS (ttm) | 91,27 |
| Prossima data utili | 31 lug 2024 |
| Rendimento e dividendo (futuro) | 196,00 (4,62%) |
| Data ex dividendo | 27 set 2024 |
| Stima target 1A | 4.751,90 |
GlobeNewswireHUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously
© 2024 Yahoo. Tutti i diritti riservati.